Positive Phase III results for fitusiran in hemophilia


Positive Phase III results for fitusiran in hemophilia

Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials.

Positive Phase III results from two trials are to be presented on fitusiran at the upcoming American Society of Hematology (ASH) meeting.

Development of the drug has been far from plain sailing.

In 2017, clinical studies with fitusiran were placed on hold following reports of a fatal thrombotic event in…

Try before you buy

7 day trial access

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

or £77 per month

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

If you are already a registered user pleaselogin.
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK

Alnylam PharmaceuticalsASHBiotechnologyConferencesDrug TrialfitusiranFranceHematologyResearchSanofiUSA

Back to top